ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.906,08
-0,49%
S&P 500
5.942,47
1,26%
Dow Jones
42.732,13
0,80%
Euro vs US Dollar
1,03115
0,00%
Bitcoin
98.304,52
0,10%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. NuCana PLC (NCNA) Börsenkurse

NuCana PLC

NuCana PLC (NCNA)

NASDAQ
1,31
0,07
(5,65%)
Geschlossen 05 Januar 10:00PM
Verzögert um 15 Minuten
1,31
0,00
(0,00%)
Nach Börsenschluss: 1:43AM
Verzögert um 15 Minuten

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
1,31
Gebot
1,30
Fragen
1,45
Volumen
153.583
1,2608 Tagesbereich 1,3677
0,00 52-Wochen-Bereich 0,00
Marktkapitalisierung
2,948M
Handelsende
1,24
Handelsbeginn
1,28
Letzte Trade
175
@
1.31
(formt)
Letzter Handelszeitpunkt
Finanzvolumen
US$ 201.071
VWAP
1,3092
Durchschnittliches Volumen (3 Mio.)
-
Ausgegebene Aktien
2.250.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-0,11
Gewinn pro Aktie (EPS)
-12,28
Erlöse
-
Nettogewinn
-27,63M

Über NuCana PLC

NuCana PLC is a biopharmaceutical company focused on improving treatment outcome for cancer patients by ProTide technology. Utilising proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of ... NuCana PLC is a biopharmaceutical company focused on improving treatment outcome for cancer patients by ProTide technology. Utilising proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Geographically operates through the region of the United States. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Hauptsitz
London, Gbr
Gegründet
-
NuCana PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NCNA. The last closing price for NuCana was US$1,24. Over the last year, NuCana shares have traded in a share price range of US$ 0,00 to US$ 0,00.

NuCana currently has 2.250.000 shares in issue. The market capitalisation of NuCana is US$2,79 million. NuCana has a price to earnings ratio (PE ratio) of -0.11.

NCNA Neueste Nachrichten

Weitere Nachrichten

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

25 November 2024
Edgar (US Regulatory)

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

Presented Encouraging Phase 2 Data on NUC-7738 in Combination with Pembrolizumab at the European Society for Medical Oncology (ESMO) Congress 2024 Announced Promising Phase 1b/2 Data on NUC-3373...

25 November 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

12 November 2024
Edgar (US Regulatory)

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival...

11 November 2024
GlobeNewswire Inc.

Form 424B5 - Prospectus [Rule 424(b)(5)]

01 Oktober 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

01 Oktober 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

26 September 2024
Edgar (US Regulatory)

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

EDINBURGH, United Kingdom, Sept. 25, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering...

25 September 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

16 September 2024
Edgar (US Regulatory)

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

BARCELONA, Spain, Sept. 14, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with...

14 September 2024
GlobeNewswire Inc.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

NCNA - Frequently Asked Questions (FAQ)

What is the current NuCana share price?
The current share price of NuCana is US$ 1,31
How many NuCana shares are in issue?
NuCana has 2.250.000 shares in issue
What is the market cap of NuCana?
The market capitalisation of NuCana is USD 2,79M
What is the 1 year trading range for NuCana share price?
NuCana has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the PE ratio of NuCana?
The price to earnings ratio of NuCana is -0,11
What is the reporting currency for NuCana?
NuCana reports financial results in GBP
What is the latest annual profit for NuCana?
The latest annual profit of NuCana is GBP -27,63M
What is the registered address of NuCana?
The registered address for NuCana is 77 78 CANNON STREET, ENGLAND, LONDON, EC4N 6AF
Which industry sector does NuCana operate in?
NuCana operates in the PHARMACEUTICAL PREPARATIONS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
FCUVFocus Universal Inc
US$ 0,9499
(174,93%)
260,93M
NITON2OFF Inc
US$ 2,6306
(145,85%)
358,28M
CRNCCerence Inc
US$ 19,33
(143,76%)
161,8M
KITTNauticus Robotics Inc
US$ 3,8249
(140,56%)
104,8M
ACONAclarion Inc
US$ 0,2984
(110,14%)
305,64M
HWHHWH International Inc
US$ 0,4621
(-28,80%)
7,08M
SMSTDefiance Daily Target 2x Short MSTR ETF
US$ 5,69
(-26,30%)
24,62M
RAINRain Enhancement Technologies Holdco Inc
US$ 5,59
(-23,42%)
155,16k
PTLEPTL Ltd
US$ 9,35
(-23,30%)
967,95k
NXUNXU Inc
US$ 0,725868
(-22,78%)
7,4M
NITON2OFF Inc
US$ 2,6306
(145,85%)
358,28M
TGLTreasure Global Inc
US$ 0,382
(101,58%)
337,5M
ACONAclarion Inc
US$ 0,2984
(110,14%)
305,64M
FCUVFocus Universal Inc
US$ 0,9499
(174,93%)
260,93M
NVDANVIDIA Corporation
US$ 144,47
(4,45%)
230,01M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
NCNA
NuCana
NYSE
TR
Tootsie Roll Industries
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten